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In November 1948, Dr. Benjamin Duggar (1) announced the preparation of
aureomycin from streptomyces aureofaciens by the Lederle group of investiga-
tors. Immediately, widespread interest was aroused in this new antibiotic.
In rapid order, investigators (2, 3) reported that aureomycin was effective in
most coccal infections and in some viral-like infections. It was shown that most
organisms did not become resistant to this antibiotic, and that it was active
against many organisms unaffected by streptomycin or penicillin (4). The action
was said to be bacteriostatic rather than bactericidal (5).
CLINICAL STUDIES
The therapeutic effectiveness of topical applications of aureomycin ointment
was studied in a variety of dermatoses. The investigations here reported cover
a period of six months, from May to November of 1949. Of the salts of aureomycin
used, the most suitable preparation was found to be aureomycin hydrochloride,
made up in a base of lanolin, mineral oil and petrolatum, 30 milligrams to the
gram. (3%). This ointment is stable and does not require refrigeration.
A total of 170 patients were treated with this preparation. The results are
tabulated in the accompanying charts.
CUTANEOUS SENSITIVITY
In the group studied, 5 cases of mild contact dermatitis were observed; the
dermatitis cleared within a week following cessation of therapy. A positive 48
hour patch test was elicited in two of these clinical reactors; the other three
gave negative patch test results.
Seventy-four of the patients were subjected to the usual 48 hour patch testing
two weeks, and again four weeks, after the initiation of therapy. A positive test
was obtained in two of the seventy-four (both in the aforementioned cases of
mild clinical dermatitis) and an equivocal reaction in two others.
SUMMARY AND CONCLUSIONS
A total of 170 patients, presenting a wide range of dermatoses were treated
with aureomycin hydrochloride ointment (Lederle); 74 of these patients were
patch tested two weeks, and again four weeks, after the initiation of therapy.
* From the Department of Dermatology and Syphilology of New York University-Post
Graduate Medical School (Dr. Marion B. Sulzberger, Chairman) and the Skin and Cancer
Unit of the New York University Hospital.
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Our findings lead us to believe that aureomycin ointment (Lederle) is a potent
therapeutic agent in the management of the superficial pyodermas. Stasis ulcers
TABLE I
DISEASE NO-OPCASES
IN
PROVED FAILED
NO.OF
DAYS SIDE REACTIONS
Impetigo contagiosa
Sycosis vulgaris
Ecthyma
Stasis ulcer
Chronic hand eczemas...
Nummular eczema
17
18
16
15
32
6
17
7
16
0
3
0
0
7
0
15*
6
2*
0
4
0
0
23
4
2— 7
7—28
3—14
7—28
7—28
7—28
None
1 mild contaut dermati-
tis
-
None
2 mild contact dermati-
tis
2 mild contact dermati-
tis
None
* Secondary bacterial infection.
TABLE II
DISEASE 0 FA CLEARED IMPROVED FAILED NO. OFDAYS SIDEREACTIONS
Seborrheic dermatitis
Herpes simplex recurrens
Verruca vulgaris
Acne vulgaris
Atopic dermatitis
Pustular bacterid hands
13
10
9
7
9
3
0
0
0
0
0
0
5
0
0
0
6*
0
8
10
9
7
3
3
28
14
28
28
28
28
None
None
None
None
None
None
* Secondary bacterial infection.
TABLE III
DISEASE CLEARED IMPROVED FAILED
NO. OF
REED REACTIONS
Psoriasis
Parapsoriasis, guttate
Itosacea
Molluscum contagiosum
Lichen planus
Erythroplasia of queyrat
3
2
4
2
3
1
0
0
0
0
0
0
0
0
0
0
0
-
0
3
2
4
2
3
1
28
28
28
28
28
28
None
None
None
None
None
None
respond rapidly, but not completely, apparently by control of the secondary in-
fection so frequently .present. Similarly, other dermatoses characterized by sec-
ondary bacterial infeetion are benefited by the ointment. Herpes simplex, ver-
ruca vulgaris, chronic hand eczemas and a miscellaneous group of dermatoses
were, in the main, uninfluenced by the therapy.
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